So this is a Phase I trial, doesn’t that mean that it has many hurdles to go?
“An important challenge in the continued development of PfSPZ Vaccine is that the vaccine currently is administered intravenously—a rare delivery route for vaccines. Previous studies at lower doses have shown that the more common intradermal (into the skin) and subcutaneous (under the skin) routes did not yield as strong an immune response as the intravenous route.”
So about the intravenous challenge, doesn’t that mean that this Phase I PfSPZ vaccine is more risky to use than a subcutaneous one, or not?
Since there is already a Phase III vaccine, then Asanta, does that mean that the Phase III vaccine has passed all but the biggest hurdles? The link that I had posted to that other thread has expired, so this link updates the expired one:GlaxoSmithKline Vaccines (GSK) RTS,S AS01 .